H
31.75
1.18 (3.86%)
| Previous Close | 30.57 |
| Open | 30.90 |
| Volume | 257,698 |
| Avg. Volume (3M) | 439,157 |
| Market Cap | 1,165,212,288 |
| Price / Earnings (Forward) | 50.76 |
| Price / Sales | 7.45 |
| Price / Book | 35.10 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 |
| Profit Margin | -10.19% |
| Operating Margin (TTM) | -23.48% |
| Diluted EPS (TTM) | -0.610 |
| Quarterly Revenue Growth (YOY) | 38.30% |
| Total Debt/Equity (MRQ) | 410.02% |
| Current Ratio (MRQ) | 0.910 |
| Operating Cash Flow (TTM) | 2.09 M |
| Levered Free Cash Flow (TTM) | -26.88 M |
| Return on Assets (TTM) | 0.90% |
| Return on Equity (TTM) | -37.31% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Harrow, Inc. | Bullish | Bullish |
AIStockmoo Score
2.8
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 2.75 |
|
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 15.07% |
| % Held by Institutions | 57.11% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 76.00 (Cantor Fitzgerald, 139.37%) | Buy |
| Median | 67.00 (111.02%) | |
| Low | 63.00 (BTIG, 98.43%) | Buy |
| Average | 68.50 (115.75%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 46.23 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B. Riley Securities | 01 Oct 2025 | 74.00 (133.07%) | Buy | 48.37 |
| 23 Sep 2025 | 70.00 (120.47%) | Buy | 48.85 | |
| BTIG | 29 Sep 2025 | 63.00 (98.43%) | Buy | 48.40 |
| 24 Sep 2025 | 63.00 (98.43%) | Buy | 47.88 | |
| HC Wainwright & Co. | 29 Sep 2025 | 64.00 (101.57%) | Buy | 48.40 |
| 13 Aug 2025 | 64.00 (101.57%) | Buy | 36.50 | |
| Lake Street | 29 Sep 2025 | 70.00 (120.47%) | Buy | 48.40 |
| Craig-Hallum | 23 Sep 2025 | 64.00 (101.57%) | Buy | 48.85 |
| Cantor Fitzgerald | 11 Jul 2025 | 76.00 (139.37%) | Buy | 34.93 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Oct 2025 | Announcement | ImprimisRx Announces Leadership Changes |
| 26 Sep 2025 | Announcement | Harrow to Acquire Melt Pharmaceuticals |
| 25 Sep 2025 | Announcement | Harrow Launches Harrow Access for All (HAFA) |
| 15 Sep 2025 | Announcement | Harrow Announces Agenda and Speakers for Investor & Analyst Day |
| 08 Sep 2025 | Announcement | Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030 |
| 08 Sep 2025 | Announcement | Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030 |
| 11 Aug 2025 | Announcement | Harrow Announces Second-Quarter 2025 Financial Results |
| 06 Aug 2025 | Announcement | Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference |
| 29 Jul 2025 | Announcement | Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025 |
| 17 Jul 2025 | Announcement | Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |